? While preliminary research into cannabinoid compounds shows promise for treating widespread conditions, clinicians should exercise caution in translating these findings into practice given the typically small sample sizes, short follow-up periods, and mechanistic uncertainty that characterize early-stage cannabis research. The gap between “may help” in laboratory or animal models and clinical efficacy in real patients remains substantial, and most cannabis-based interventions lack the robust evidence standards required for confident therapeutic recommendation. Additionally, patient access to standardized, quality-controlled cannabis products varies widely by jurisdiction, and concurrent use with other medications may create unpredictable interactions that complicate treatment plans. Until larger, well-designed clinical trials establish clear efficacy and optimal dosing, the most prudent clinical approach is to remain appropriately skeptical of media reports about cannabis as a disease-reversing agent while staying informed about evolving evidence. When patients raise questions about cannabis for their condition, providers can acknowledge the